Skip to main content

Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

IASLC 20th World Conference on Lung Cancer
Independent satellite symposium

Simplifying the sequencing of treatment in NSCLC with no actionable mutations

Saturday 7 September 2019, at 16:00 CEST.
Copenhagen (1980) room, Gran Via Venue, Fira de Barcelona

Refreshments and snacks will be available before the symposium.

This independent symposium, led by an expert international faculty, will discuss non-small-cell lung cancer (NSCLC) treatment choices and share a case study in the first-line setting, set against current standards in care and the latest clinical trial data. Two subsequent case studies will then focus on how to treat patients in the complex second-line setting alongside latest data, and how to identify and classify hyperprogressive disease. Finally, the Faculty will explore how to balance between promise and reality in order to overcome barriers for integration and uptake of suitable new treatments in different global regions. 

Learning objectives

After attending the symposium and/or reviewing the enduring materials, the participants will be
able to:

  • Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
  • Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
  • Explain how to identify hyperprogressive disease and its influence on treatment decisions


Time (CEST)


16:00 – 16:10

Welcome and Introduction
Corey Langer

16:10 – 16:35

Where should we begin?
Enriqueta Felip

16:35 – 17:00

Navigating the increasingly complex second-line setting
David Heigener

17:00 – 17:15

Special considerations for hyperprogressive disease
Myung-Ju Ahn

17:15 – 17:25

Panel and audience discussion: Bridging the gap between promise and reality

17:25 – 17:30

Corey Langer



This symposium has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



Target audience

The symposium and enduring materials will be targeted at international (medical and radiation) oncologists and any other healthcare professionals involved in the diagnosis, treatment and follow-up of patients with lung cancer.

Educational grant

This program was made possible thanks to an independent educational grant from Eli Lilly and Company.

Contact Us

Springer Healthcare IME.

Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK

Enriched treatment pathway